Both feed and pig business have made a profit, Tiankang Bio made a profit of 600 million to 700 million last year.
In 2019, Tiankang Bio estimates that the net profit attributable to shareholders of listed companies will be 600 million to 700 million yuan, an increase of 91.25% to 123.12% over the same period of the previous year.
Beijing News (Reporter Yan Xia) On the evening of January 16, Tiankang Bio released a 2019 annual performance forecast.
In 2019, Tiankang Bio estimates that the net profit attributable to shareholders of listed companies is 600 million to 700 million yuan, an increase of 91.5% to 123.12% over the same period of the previous year.
Regarding the reasons for the change in performance, Tiankang Bio explained: “During the reporting period, after the company’s new breeding base was put into production, the scale of breeding expanded. In 2017, 827,700 live pigs were sold, an increase of 30.33% compared with the same period in 2018. Due to the tight supply of hogs, the sales price of hogs rose, and the company’s hog breeding business income and profit rose sharply year-on-year, with annual revenue of 1.501 billion yuan, an increase of 110.81% over the same period in 2018; during the reporting period, the sales scale of feed business continued to increase The growth of the business is steady; the pharmaceutical business is affected by the non-plague situation, and the performance has declined. “
According to the official website, Tiankang Bio is a listed agricultural and livestock listed company integrating veterinary biological products and animal disease control, modern pig scientific breeding and breeding, feed research and development and production, and pig slaughtering, processing and distribution.
According to Tiankang Bio’s 2018 annual report, in 2018, its feed business sales revenue, pharmaceutical business sales revenue, hog breeding and food processing business sales revenue accounted for 48.59%, 14.22%, 16.21%.
Beijing News reporter Yan Xia
Editor Chen Shiyi Proofreading Wu Xingfa